company background image
COG

Cambridge Cognition HoldingsAIM:COG Stock Report

Market Cap

UK£38.7m

7D

1.2%

1Y

114.7%

Updated

27 Nov, 2021

Data

Company Financials +
COG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends0/6

COG Stock Overview

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health solutions in the United States, United Kingdom, the European Union, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Cambridge Cognition Holdings
Historical stock prices
Current Share PriceUK£1.25
52 Week HighUK£1.95
52 Week LowUK£0.54
Beta1.13
1 Month Change-9.46%
3 Month Change-19.94%
1 Year Change114.66%
3 Year Change19.71%
5 Year Change76.60%
Change since IPO55.63%

Recent News & Updates

Shareholder Returns

COGGB Healthcare ServicesGB Market
7D1.2%-2.0%-3.0%
1Y114.7%15.7%11.7%

Return vs Industry: COG exceeded the UK Healthcare Services industry which returned 15.7% over the past year.

Return vs Market: COG exceeded the UK Market which returned 11.7% over the past year.

Price Volatility

Is COG's price volatile compared to industry and market?
COG volatility
COG Average Weekly Movement6.6%
Healthcare Services Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: COG is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: COG's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201258Matthew Storkhttps://www.cambridgecognition.com

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health solutions in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer’s disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I–IV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; and CANTAB Insight, a medical device that helps to determine an individual’s cognitive health.

Cambridge Cognition Holdings Fundamentals Summary

How do Cambridge Cognition Holdings's earnings and revenue compare to its market cap?
COG fundamental statistics
Market CapUK£38.66m
Earnings (TTM)UK£70.00k
Revenue (TTM)UK£8.23m

553.3x

P/E Ratio

4.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COG income statement (TTM)
RevenueUK£8.23m
Cost of RevenueUK£1.65m
Gross ProfitUK£6.58m
ExpensesUK£6.51m
EarningsUK£70.00k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.0022
Gross Margin79.95%
Net Profit Margin0.85%
Debt/Equity Ratio0.0%

How did COG perform over the long term?

See historical performance and comparison

Valuation

Is Cambridge Cognition Holdings undervalued compared to its fair value and its price relative to the market?

553.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: COG (£1.25) is trading above our estimate of fair value (£1.23)

Significantly Below Fair Value: COG is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COG is poor value based on its PE Ratio (553.3x) compared to the European Healthcare Services industry average (54.5x).

PE vs Market: COG is poor value based on its PE Ratio (553.3x) compared to the UK market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: COG is poor value based on its PEG Ratio (7.7x)


Price to Book Ratio

PB vs Industry: COG is overvalued based on its PB Ratio (148.2x) compared to the GB Healthcare Services industry average (4.5x).


Future Growth

How is Cambridge Cognition Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

71.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COG's forecast earnings growth (71.7% per year) is above the savings rate (0.9%).

Earnings vs Market: COG's earnings (71.7% per year) are forecast to grow faster than the UK market (12.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: COG's revenue (16.1% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: COG's revenue (16.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if COG's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Cambridge Cognition Holdings performed over the past 5 years?

-24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COG has high quality earnings.

Growing Profit Margin: COG became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: COG has become profitable over the past 5 years, growing earnings by -24.7% per year.

Accelerating Growth: COG has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: COG has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (31.2%).


Return on Equity

High ROE: Whilst COG's Return on Equity (26.82%) is high, this metric is skewed due to their high level of debt.


Financial Health

How is Cambridge Cognition Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: COG's short term assets (£9.3M) do not cover its short term liabilities (£9.6M).

Long Term Liabilities: COG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: COG is debt free.

Reducing Debt: COG has not had any debt for past 5 years.

Debt Coverage: COG has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: COG has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Cambridge Cognition Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate COG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate COG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if COG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of COG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Matthew Stork

2.5yrs

Tenure

UK£388,000

Compensation

Dr. Matthew Stork has been the Chief Executive Officer at Cambridge Cognition Holdings Plc since May 24, 2019 and has been its Director since May 23, 2019. He was Chief Operating Officer of Cambridge Cogni...


CEO Compensation Analysis

Compensation vs Market: Matthew's total compensation ($USD516.71K) is above average for companies of similar size in the UK market ($USD324.88K).

Compensation vs Earnings: Matthew's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: COG's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: COG's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cambridge Cognition Holdings Plc's employee growth, exchange listings and data sources


Key Information

  • Name: Cambridge Cognition Holdings Plc
  • Ticker: COG
  • Exchange: AIM
  • Founded: 2012
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: UK£38.662m
  • Shares outstanding: 31.05m
  • Website: https://www.cambridgecognition.com

Number of Employees


Location

  • Cambridge Cognition Holdings Plc
  • Tunbridge Court
  • Tunbridge Lane
  • Cambridge
  • Cambridgeshire
  • CB25 9TU
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/27 18:52
End of Day Share Price2021/11/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.